Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $294.25.

JAZZ has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Deutsche Bank upped their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Finally, Weiss Ratings lowered Jazz Pharmaceuticals from a “hold (c+)” rating to a “hold (c-)” rating in a research note on Thursday.

Check Out Our Latest Stock Report on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $241.55 on Monday. The company has a market capitalization of $15.51 billion, a price-to-earnings ratio of 82.16, a PEG ratio of 0.44 and a beta of 0.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a 12-month low of $139.26 and a 12-month high of $266.38. The firm’s 50-day moving average price is $229.13 and its two-hundred day moving average price is $219.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company earned $8.13 EPS. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. On average, analysts forecast that Jazz Pharmaceuticals will post 11.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,413 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total value of $326,911.68. Following the sale, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at $1,506,616.32. This trade represents a 17.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Neena Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president owned 47,671 shares in the company, valued at approximately $11,485,850.74. This represents a 2.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 171,342 shares of company stock worth $41,420,491 over the last quarter. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. USA Financial Formulas bought a new stake in shares of Jazz Pharmaceuticals during the first quarter worth $25,000. Pension & Wealth Management Advisors Inc. bought a new position in Jazz Pharmaceuticals in the third quarter valued at about $32,000. Ameritas Advisory Services LLC bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $47,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at about $61,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 158 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Further Reading

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.